Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19

June 18, 2020

During the COVID-19 pandemic, challenges to the conduct of clinical trials may arise, e.g. due to travel restrictions or quarantines, interruptions to supply chains, or when site personnel or trial subjects become infected with SARS-CoV-2.

Previous Flipbook
COVID-19 Lay Summary EMA Management of Clinical Trials
COVID-19 Lay Summary EMA Management of Clinical Trials

Next Article
Putting the Pandemic in Plain Language
Putting the Pandemic in Plain Language

The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including ...